BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
$5.34-3.61%
报价 2026-11-06
市值
$201M
EV
$138.2M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -78.7%
$4.84$25.10
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BIOABioAge Labs, Inc. | $201M | -3.6% | -16.9% | 99.4% | – | – | – | |
| TKNOAlpha Teknova, Inc. | $481.9M | -0.9% | +9.5% | 33.9% | – | – | – | |
| EDITEditas Medicine, Inc. | $394.7M | +0.8% | -41.9% | 56.9% | – | – | – | |
| ALLOAllogene Therapeutics, Inc. | $359.3M | -4.6% | – | 0% | – | – | – | |
| AVIRAtea Pharmaceuticals, Inc. | $345.7M | +2.1% | -19.7% | 0% | – | – | – | |
| ACBAurora Cannabis Inc. | $344.5M | +1.0% | – | -5.9% | – | – | – | |
| CGCCanopy Growth Corporation | $275.6M | -3.6% | – | 27.4% | – | – | – | |
| LFCRLifecore Biomedical, Inc. | $241.1M | -0.6% | +62.7% | 29.7% | – | – | – | |
| CABACabaletta Bio, Inc. | $220.4M | +1.6% | -43.2% | 0% | – | – | – | |
| 同行中位数 | – | – | -19.7% | 13.7% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。